Interleukin-5 (IL-5) Therapy Prevents Allograft Rejection by Promoting CD4+CD25+ Ts2 Regulatory Cells That Are Antigen-Specific and Express IL-5 Receptor

Bruce M. Hall1,2†, Rachael M. Hall1,2, Giang T. Tran1,2†, Catherine M. Robinson1,2, Paul L. Wilcox1,2, Prateek K. Rakesh1,2, Chuanmin Wang3, Alexandra F. Sharland3†, Nirupama D. Verma1,2† and Suzanne J. Hodgkinson1,2†

1 Immune Tolerance Laboratory, South West Clinical School, University of New South Wales (UNSW) Sydney, Liverpool, NSW, Australia, 2 Ingham Institute of Applied Medical Research, Liverpool Hospital, Liverpool, NSW, Australia, 3 Transplantation Immunobiology Group, Central Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

CD4+CD25+Foxp3+T cell population is heterogeneous and contains three major subgroups. First, thymus derived T regulatory cells (tTreg) that are naïve/resting. Second, activated/memory Treg that are produced by activation of tTreg by antigen and cytokines. Third, effector lineage CD4+CD25+T cells generated from CD4+CD25- T cells' activation by antigen to transiently express CD25 and Foxp3. We have shown that freshly isolated CD4+CD25+T cells are activated by specific alloantigen and IL-4, not IL-2, to Ts2 cells that express the IL-5 receptor alpha. Ts2 cells are more potent than naïve/resting tTreg in suppressing specific alloimmunity. Here, we showed rIL-5 promoted further activation of Ts2 cells to Th2-like Treg, that expressed Foxp3, Irf4, Gata3 and Il5. In vivo, we studied the effects of rIL-5 treatment on Lewis heart allograft survival in F344 rats. Host CD4+CD25+ cells were assessed by FACS, in mixed lymphocyte culture and by RT-PCR to examine mRNA of Ts2 or Th2-like Treg markers. rIL-5 treatment given 7 days after transplantation reduced the severity of rejection and all grafts survived ≥60d whereas sham treated rats fully rejected by day 31 (p<0.01). Treatment with anti-CD25 or anti-IL-4 monoclonal antibody abolished the benefits of treatment with rIL-5 and accelerated rejection. After 10d treatment with rIL-5, hosts' CD4+CD25+ cells expressed more Il5ra and responded to specific donor Lewis but not self. Enriched CD4+CD25+ cells from rIL-5 treated rats with allografts surviving >60 days proliferated to specific donor only when rIL-5 was present and did not proliferate to self or third party. These cells had more mRNA for molecules expressed by Th2-like Treg including Irf4, Gata3 and Il5. These findings were consistent with IL-5 treatment preventing rejection by activation of Ts2 cells and Th2-like Treg.

Keywords: interleukin-5, transplant tolerance, T regulatory cells, cytokines, allograft rejection, chronic rejection, CD4 + CD25 + Treg cells, Th2 cytokines

Abbreviations: BSA, bovine serum albumin; HRP, horse radish peroxidase; Ipi, intra-peritoneal injection; IL-, interleukin; mAb, monoclonal antibody; PBS, phosphate buffered saline; r, recombinant; Treg, T regulatory cells.
INTRODUCTION

With current immunosuppression, organ allografts are rarely lost from acute rejection but later rejection remains a major problem (1) in all forms of organ transplantation. No current therapy is effective at its prevention or treatment (2–4). Induction of alloantigen specific tolerance is a potential therapy to prolong graft survival.

Rejection is a complex immunological process, starting with CD4+T cell activation by donor alloantigen (4, 5) resulting in a mononuclear cell infiltrate, T cell mediated injury (6, 7) and antibody deposition (8) with activation of complement (9). This leads to slow destruction of the allograft from vascular injury (10), destruction of the microcirculation (11, 12) and leads to slow destruction of the allograft from vascular injury (10), destruction of the microcirculation (11, 12) and fibrosis (1).

The most frequently studied Treg are naïve/resting thymus derived CD4+CD25+Foxp3+T cells (tTreg) (13, 14) however these alone do not mediate transplant tolerance. Transplanted (10), destruction of the microcirculation (11, 12) and leads to slow destruction of the allograft from vascular injury (10), destruction of the microcirculation (11, 12) and fibrosis (1).

The precise pathway for activation of alloantigen specific CD4+CD25+Foxp3+Treg that are still not known, however. We have previously shown activation of naïve/resting Treg with specific-alloantigen and the Type-1 cytokine IL-2 induces a population of more potent antigen-specific Treg that express Ifngr and Il12rb2 (28, 29). We have called these cells Ts1. Ts1 cells are promoted by alloantigen and the Th1 cytokines IFN-γ and/or IL-12 to Th1-like Treg that suppress at very low ratios (23) and can induce transplant tolerance.

In a rejection response, there is also activation of Th2, Th17 and other cell types that produce different cytokines to Th1 cells. These different cytokines in presence of alloantigen also promote activation of naïve Treg by separate pathways.

Relevant to this study, we described a second pathway of Treg activation by Type-2 cytokines (28, 29) (Figure 1). Activation of Treg by IL-4 a Type 2 cytokines is independent of IL-2, as tTreg express the IL4Rα. tTreg cultured with recombinant (r) IL-4 and alloantigen develop into more potent activated Treg that prevent allograft rejection mediated by naive CD4+T cells at a ratio of 1:10 and suppress specific anti-donor responses in MLC at ratios of 1:32 to effector CD4+CD25+ cells (29). In contrast, fresh naïve CD4+CD25+ cells only fully suppress allograft rejection or anti-donor responses in MLC at 1:1 (26, 31). We called these IL-4 and antigen activated Treg, Ts2 cells (29). Ts2 cells express IL-5Rα, the specific-receptor for the Type 2 cytokine IL-5 (29), and are activated by IL-5 in the presence of specific antigen (30, 32). Using cells from animals tolerant to an allograft, we have shown that IL-5 promotes

---

**TABLE 1** | Definition of subpopulations of cells within peripheral lymphoid CD4+CD25+Foxp3+T cells relevant to this study.

| Thymic derived naive/resting Treg. | Thymus derived CD4+CD25+Foxp3+T cells that have not been activated by antigen since leaving the thymus. Known as tTreg or nTreg. These cells are the majority of CD4+CD25+Foxp3+T cells in naïve animals. |
| Activated/memory Treg | Thymus derived CD4+CD25+Foxp3+Treg that are activated by antigen in the periphery in the presence of cytokines that induces higher expression of CD25 and Foxp3 than in tTreg |
| Peripheral/induced Treg | Effector lineage CD4+CD25+Foxp3+T cells that have been activated by specific antigen in the absence of inflammatory cytokines such as IL-6 and IL-1 |
| Ts1 cells | tTreg that have been activated by a specific antigen and the Type-1 cytokine IL-2. Express receptors for Type-1 cytokines IFNGR and IL-12Rβ2. |
| Th1-like Treg | Ts1 cells are 10-64 times more potent than tTreg at suppression of responses to specific-antigen. Also express Th1 associated molecules IFN-γ, Tbet, CXC93. Th1-like Treg’s suppression is 100-1000 fold more potent than tTreg |
| Ts2 cells | tTreg that have been activated by a specific antigen and the Type-2 cytokine IL-4. IL-2 is not required for induction of Ts2 cells as tTreg express IL-4Rα. Ts2 cells express receptors for Type-2 cytokine IL-5 and 10-32 times more potent at suppression of responses to specific antigen than tTreg |
| Th2-like Treg | Ts2 cells that have been activated by a specific-antigen and the Type-2 cytokine IL-5. Also express Th2 associated molecules IL-5, GATA3, IRF4 and CCR8. Suppression 100-1000 fold more potent than tTreg |
survival of tolerance-transferring CD4+T cells (33) and proliferation of CD4+CD25+T cells to specific alloantigen (31).

In rats, treatment with rIL-5 reverses autoimmunity (30, 32) and delays neonatal heart graft rejection (34), with inhibition of Th1 and Th17 while sparing of Th2 responses (30, 34). In autoimmunity, the immunosuppressive effect of rIL-5 requires host CD25+T cells to expand the immune response. In parallel, IL-4 also activates naïve/resting CD4+CD25+Foxp3+Treg (tTreg) in a polyclonal fashion and this activation does not require IL-2. Treg express IL-4Ra and can recognize graft alloantigen in the presence of IL-4 get activated to alloantigen-specific Treg that are induced to express IL-5Ra, the specific receptor for IL-5 (Bottom row). We call these activated antigen-specific CD4+CD25+Foxp3+Treg Ts2 cells (29, 30). Ts2 cells diminish the immune response by inhibition of Th1 and Th17 cells promoting polarization to a Type 2 effector response (33). A sustained Th2 response results in production of IL-5 from Th2 cells (GATA-3+), and diminished IL-4 production. In the second step of activation is IL-5 in presence of specific stimulating alloantigen promoting expansion of Ts2 (IL-5Ra+Foxp3+) to Th2-like Treg. Th2-like Treg express mRNA for Foxp3, Gata-3, Irf4 and Il5. Th2-like Treg do not express key markers of Th1-like Treg such as tbet, Ifng, Il12rb2. The presence of IL-4 during late stage of immune response inhibits induction of Th2-like Treg.

**MATERIALS AND METHODS**

**Animals**

F344 (RT1(^b)) rats were purchased from the Animal Resource Centre (Murdoch, WA, Australia). Lewis (RT-1(^l)), PVG (RT1(^a)) and DA(RT-1a) rats were bred and maintained in the animal house, Liverpool Hospital. All animals were fed standard chow and given water ad libitum. The housing and experiments were
in accordance with the Australian Code for the Care and Use of Animals for Scientific Purposes and approved by the Animal Ethics Committee of the UNSW Sydney. Rats that received standard care in the animal house and not given any treatment or alloantigen were considered naïve.

**Heterotopic Heart Graft Procedures**

F344 male rats of 200g or more were anesthetized with isoflurane and grafted with heterotopic adult Lewis hearts from 180-230g donors, as described (40). Graft function was monitored daily during the treatment period then two to three times per week. Graft function was scored as 4 for a strong and fast beat similar to an isograft, 3 for mild graft swelling and slowing of graft contraction, 2 for moderate swelling and slowing of graft heartbeat, 1 for marked swelling and slowing of contraction, 0.5 for marked bradycardia and minimal and variable contraction, and 0 if no beat was detected. Total rejection was defined as a score of 0.5 or 0 observed for 10 days. In some tolerance models, graft function can improve days after what appears to be complete rejection. Thus, we observed graft function for weeks after major rejection. Some animals were sacrificed at the end of rIL-5 treatment for histology, as described (17).

**Cytokines**

Rat rIL-5 and rat rIL-4 were produced as supernatant from a transfected CHO-K1 cell line that was cultured in serum free medium and activity assessed in bioassays as described (41, 42). Supernatant was concentrated and rIL-5 quantified in a bioassay using the IL-5 dependent cell line B13 (a gift of Dr C. Sanderson, Curtin University, Perth WA, Australia), as described (43–46). 5000 Units of rIL-5 in 0.5 ml was given ipi as a daily dose. 5000 units of rIL-5 per day is well tolerated by rats, induces Ts2 cells to reverse autoimmunity and induces eosinophilia (22).

**Treatment With Monoclonal Antibodies**

To deplete CD25+ cells, the mAb NDS61 (gift of M Dallman, Imperial College London, UK) was given ipi at 7mg/kg daily from day 3 to 17 post-transplantation (30, 47). To block IL-4, 7mg/kg MRCOx8 (gift of N Barclay, Sir William Dunn School of Pathology, Oxford, UK) was given ipi on days 3-8 post-grafting, then every second day until day 15, as described (30, 41). These mAb were produced as described (15).

**Experimental Plan for Transplant Experiments**

Five groups of F344 rats with heterotopic Lewis heart grafts (n=4-5) were studied and animals were monitored for heart allograft function. A sham treated group received saline injections daily from Day 7-16 post-transplant and four groups were given rIL-5 daily for 10 days from day 7 to 16 post-transplant. One of these four groups, the short-term rIL-5 treated, had rIL-5 therapy stopped after day 16, this group was repeated three times with results of all animals combined (n=12). Another rIL-5 treatment group, the long term treated group, had rIL-5 therapy continued as three times a week after the day 16. For the remaining two groups that received rIL-5, one was also treated with anti-CD25 mAb and the other with anti-IL-4 mAb, as described above. Some animals were used for histology of the heart graft and/or collection of spleen and lymph node cells for enrichment of CD4+CD25+T cells for MLC. At the end of experiments, at about 60 days post-transplant, all graft recipients in groups 1, 2 and 3 were sacrificed for FACS, RT-PCR and MLC studies on enriched CD4+CD25+T cells.

**Histology**

Donor heart sections were paraffin fixed and stained with hematoxylin and eosin. The histology images shown in Figure 5B were taken by a Leica DM 450C camera with 20x magnification on a Leica DM 2000 LED microscope as we have described in Figure 5B legend. For quantification of areas of myocyte necrosis and mononuclear cell infiltration these paraffin sections were assessed in multiple images taken at 400x magnification on a Zeiss Axioscope A1 microscope (Zeiss, North Ryde, Australia). Image Pro Plus 6.2 software (Media Cybernetics, Rockville, MA) was used to estimate the area of myocytes necrosis and mononuclear cell infiltration, which were expressed as pixels per high power field (HPF).

Immunohistology was performed on 5μM sections of frozen heart allografts cut on a cryostat. Sections were air dried after fixation with acetone for 10min, then stained with a two-step indirect immunoperoxidase technique, as previously described (5, 48). The primary mAb used were W3/25 to CD4, MRCOx8 to CD8 (BD), FJK-16 to Foxp3 and ED1 to CD68 on macrophages (Abcam, Cambridge, UK), as described (49). The secondary antibodies were HRP labelled anti-mouse Ig (Dako A/s, Glostrup, Denmark). Positive staining was assessed in multiple images taken at 400 X magnification on a Zeiss Axioscope A1 microscope. Image Pro Plus 6.2 software was used to estimate the area of positive staining and was expressed as pixels per high power field (HPF).

**Immunostaining of Lymphocytes**

FITC labeled anti-rat mAb used were G4.18 (CD3), W3/25 (CD4), MRCOx8 (CD8α), MRCOx39 (CD25, IL-2R alpha chain), MRCOx33 (CD45RA)(BD) and FJK-165 (anti-mouse/ rat Foxp3) (eBioscience, San Diego, CA). Staining and analysis of lymphoid cells using a FACSscan (BD, San Jose, CA) was as described (19, 50, 51).

**Cell Preparation and Subset Separation**

Single cell suspensions from spleen and lymph node were prepared as described (30, 52) and RBCs were lysed with a buffer of 0.83% NH₄Cl, 0.1% KHCO₃ and 10mM EDTA at pH 7.2. Cells were re-suspended in PBS/0.4% BSA (MultiGel, Biosciences, Castle Hill, NSW, Australia). Spleen and lymph node cells from three or more animals were pooled to provide sufficient CD4+CD25+ cells for cultures.

An indirect panning technique was used to deplete CD8⁺T and B cells, as described (14, 50). Briefly, cells were incubated for 30 minutes at 4°C with optimized concentrations of MRCOx8 (an anti-rat CD8α mAb) and MRCOx33 (a rat CD45RA mAb that binds B cells and other cells but not T cells). All mAb were purchased from ThermoFischer. Cells were washed with PBS/
0.4%BSA, re-suspended at 2x10^7 cells/ml and incubated for an hour on Petri dishes (Greiner Bio-one, Kremsmunster, Austria) coated with both rabbit anti-mouse Ig and rabbit anti-rat Ig (Dako). The unbound CD4^+ cells were collected and incubated at 4°C for 20 min with PE conjugated MRCox39 (BD) (an anti-rat CD25 mAb), then washed twice before 8µl/10^6 cells were incubated for 15 min at 4°C with anti-PE microbeads (Miltenyi). Enriched CD4^+CD25^+ cells were then eluted through a LS MACS column (Miltenyi) and were re-suspended in RPMI 1640 media with 20% Lewis rat serum for culture. Cell subsets were subjected to immunostaining with mAb. Enriched cells were 97-99% CD4^+ and 80-95% CD25^. 60-80% of these CD4^+CD25^+T cells were Foxp3^+.

For RT-PCR and cell culture in MLC, CD4^+CD25^-T cells were re-suspended in PBS/0.4%BSA.

**Assays of Proliferation of CD4^+CD25^+T Cells in MLC**

Stimulator cells were prepared from irradiated (25 gray) thymus cells, as described^19^ In each experiment parallel cultures with self (F344), specific donor (Lewis), third party (PVG) stimulator cells or no stimulator cells were performed. Cell culture medium was RPMI 1640 (GIBCO, Grand Island, NY) supplemented with 100 ng/ml penicillin, 100 U/ml streptomycin (Glaxo, Boronia, Victoria, Australia), 2 mM L-glutamine, 5x10^{-3}M 2-mercaptoethanol (Sigma), and 20% Lewis rat serum. 20% Lewis rat serum produces low background stimulation in autologous controls (19). Cultures with 5-6 replicates for each experimental group were set up in U-bottom micro-titer plates (Linbro, Flow Labs, VA) containing 2 x 10^4 stimulators cells and 1 x 10^5 CD4^+CD25^- cells/well in a total volume of 200 µl. To assess the effects of rIL-5 on proliferation of these cells, 200 U/ml of rIL-5 was added to some cultures, as described (30, 32). Where stated CD4^+CD25^-T cells naïve animals were cultured with rIL-4 (200 units/ml) as described (29).

Cells were cultured at 37°C in humidified air containing 5% CO₂ for 4 days, the peak of CD4^+CD25^-T cell proliferation (26). 0.5uCi ^3H^-thymidine (TRK-120, Amersham, Arlington Heights, IL) was added 16hr prior to harvesting with a Tomtec Cell Harvester (Flow Lab, Ayrshire, Scotland). Proliferation was assayed by adding liquid scintillation uid before counting on a beta counter (1450 Microbeta Plus, Beckman Instruments, Palo Alto, CA). Each experiment has 5-6 replicates and results were expressed as cpm and presented as mean +/- standard deviation (SD). Counts of <400/min were considered within the range of background

The effect of rIL-5 on CD4^+CD25^-T cells proliferation in culture was calculated as a Stimulation Index using the formula: proliferation of cells with rIL-5 to a defined antigen divided by proliferation to the same defined antigen without rIL-5.

**RT-PCR of Cytokines and Cytokine Receptors**

mRNA extraction from cells and reverse transcription to DNA were as described (21). Primers for rat Foxp3, Gata3, Tbet, Il2, Il4, Il5, Ifng, Ifngr, Il5ra, Il12rb2 and Gapdh were as previously reported (28–30, 53). The primers for Irf4 were F-TGTCCT CCGTGAGCTGTCT; R- CCTGGATCGGCTCCTCCTATG, as described (49). The panel of molecules examined were selected for their relevance to Treg activation. Real-time PCR was performed as described (54) with a Rotorgene (Corbett Research) and SYBR Green I detection. Sensimix Taq polymerase (BioLine) was used according to manufacturer’s instructions. Copy numbers of each gene was derived from a known standard curve performed in parallel and normalized against Gapdh expression.

**Statistics**

Parametric data were expressed as mean ± standard deviation. Results from repeat experiments were pooled, with replicates of ≥ 3 in each experiment. Means were compared using t test with GraphPad Prism (Graphpad Software Inc, La Jolla, CA). Statistical significance was set at p< 0.05.

**RESULTS**

**RT-PCR of mRNA From Naïve CD4^+CD25^- Cells After Culture in MLC With Alloantigen and Type 2 Cytokines**

To establish the changes in alloantigen activated Treg during Type 2- responses, we examined cytokines, cytokine receptors and transcription factors that are induced after naïve/resting CD4^+CD25^-T cells are cultured first with alloantigen and rIL-4 and later in a second culture with specific alloantigen and rIL-5. The experimental protocol is illustrated in Figure 2A. The hypothesis was that rIL-4 and alloantigen would activate naïve/resting CD4^+CD25^-Treg to Ts2 cells expressing IL-5Rα that would proliferate when stimulated by specific-alloantigen and rIL-5 (29, 30, 32) and develop into Th2-like Treg.

CD4^+CD25^-T cells from naïve DA rats were cultured for 4 days with fully allogeneic PVG stimulator cells and 200 units of rIL-4 as described (29) to induce Ts2 cells. These Ts2 cells were washed and re-cultured with 200 units of rIL-5 and the same alloantigen to induce Th2-like Treg. Combined results from three separate experiments of RT-PCR of mRNA of these cells are shown in Figure 2B. The Th2-like Treg had increased expression of mRNA for the transcription factors Foxp3, Irf4, and Gata-3, but had no induction of Tbet. Il5 but not Il4, Il2 or Ifng was induced in these cells. Compared to starting CD4^+CD25^-T cells from naïve rats where naïve/resting Treg (CD4^+CD25^-Foxp3^-Treg) forms a major part, II5ra expression was increased in Ts2 cells, but this increase was not sustained in Th2-like Treg. We used expression of Irf4 and Il5 as markers for Th2-like Treg induction.

**Effect of rIL-5 Treatment on Lewis Heart Graft Rejection in F344 Rats**

Our hypothesis is that during a rejection response, some Th2 cells will be activated to produce IL-4 that with donor antigen would activate naïve/resting CD4^+CD25^-Foxp3^-Treg to Ts2 Treg as proposed in Figure 1. Lewis heterotopic cardiac allografts into F344 rats are slow to reject as there is only a
single class I MHC and multiple minor incompatibilities with no class II MHC incompatibility (27, 28). The model is delayed acute rejection with T cell activation and infiltration. The experimental plan is shown in Figures 3A and 4A. Graft function was scored using a semi-quantitative scale described in methods and mean heart graft function score are presented on y-axis (Figures 3B, 4B).

Rejection in sham treated hosts (n=8) caused a decline in graft function after day 10, with complete rejection by day 31 (Figure 3B). No rats in this sham treated control group...
recovered to have significant function, with graft function scores of 0.5 or 0. Short-term rIL-5 treatment (n=12) was 5000 units ip daily for 10 days between 7 and 16 days post-transplantation (Figure 3A). In the long-term treatment group (n=5), rIL-5 therapy was continued three times a week immediately following the daily rIL-5 from 7 to 16 days post-transplant (Figure 3A). In both rIL-5 treated groups, graft function scores were higher than in sham treated rats at all time points beyond day 10 post-transplant (p<0.01) (Figure 3B). rIL-5 treatment preserved graft function, with all grafts scoring ≥2 until cessation of rIL-5 treatment at day 16. The graft function score was significantly higher than sham treated group, p<0.01 at day 16 and p<0.001 at day 17 (Figure 3B).

Heart graft function in both rIL-5 treatment groups stabilized around 20 days post-transplant then improved. The group that
received long-term treatment with rIL-5 therapy had more rapid improvement in graft function, with scores significantly higher than sham treated controls at all time points beyond day 22 (p<0.05). Compared to 10-day treatment group, the long-term rIL-5 treated group had higher graft function scores on day 35 (p=0.05) and 40 (p<0.01) (Figure 3B). By day 43, both rIL-5 treated groups had a mean graft function score of 3. At the end of monitoring on day 60, 3 of 5 long-term rIL-5 treated rats had an excellent graft function score of 4 and another rat had a score of 3 (Figure 3B). This level of heart graft function is consistent with operational transplant tolerance and similar to long-term syngeneic heart graft function in this rat allograft model, as observed in previous studies.

**Depletion of CD25+ Cells Prevented rIL-5 Treatment Slowing Rejection**

The rationale for rIL-5 treatment was to expand CD4+CD25+ Foxp3+Treg that had been activated by IL-4 produced in the early rejection response. NDS61, a mAb to rat CD25, depletes CD4+CD25+T cells in rats (47) and prevents rIL-5

---

**FIGURE 4 |** Blocking IL-4 or depleting CD25+ cells prevents rIL-5 treatment inhibiting rejection of Lewis heterotopic heart allografts in F344 recipients. (A) Experimental Flow Chart. All groups received 5000 units of rat rIL-5 daily (ip) in 0.5ml. One group was treated with anti-CD25 mAb (NDS61) (n=4) and another with MRC OX81 (n=4), as described in methods. A control group received rIL-5 treatment from day 7-16 post transplantation, as in Figure 3, with no blocking mAb (○). Rejection scores are expressed as mean ± standard deviation. (B) Graft survival anti-CD25 mAb treated. Anti-CD25 treated (△) rats had more severe graft rejection than rIL-5 treated alone with significant differences from day 15 onwards to day 40 post-transplant (p<0.05). All grafts had fully rejected by day 19, and none recovered. Significance compared to rIL-5 treated controls; ✧ p<0.05, ✧✧ p<0.01; ✧✧✧ p < 0.001. Graft Survival anti-IL-4 treated. Animals treated with anti-IL-4 mAb (□) rejected their transplants more rapidly than rats treated with rIL-5 alone, with significant differences from day 9 (p<0.05) and on all subsequent days (p<0.01). All grafts were fully rejected by day 17 and none recovered. Significance compared to rIL-5 treated controls; *p < 0.05, **p < 0.01, ***p < 0.001. Taken together, these studies showed host CD25+T cells, presumably naive Treg, were required as was host IL-4 to induce a state where rIL-5 therapy could delay rejection and promote long-term allograft survival.
treatment inhibiting autoimmune responses (30, 32). To
demonstrate a role for CD25+ cells, we depleted these cells by
ipi of NDS61 daily from 3 to 17 days post-transplantation,
as illustrated in Figure 4A. Hosts depleted of CD25+T cells
and treated with rIL-5 rejected their allografts faster, with
all allografts fully rejected at day 19 (n=4) (Figure 4B). No
graft function was detected in any animal treated with NDS61
and rIL-5 after day 20 and there was no recovery in graft function
in the next 10 days. Graft rejection was more severe in anti-
CD25 mAb and rIL-5 treated rats (Figure 4B) than in sham
treated from day 14 to 19 (p<0.05) (Figure 3B). This suggests
CD25+ cells are activated during rejection and slow the progress
of rejection.

Blocking IL-4 Inhibited the Effects of rIL-5
Treatment on Preventing Rejection
MRCox81, a mAb that blocks IL-4 (40, 41), was administered
daily from day 3-8 then on days 10,12,14 post-transplantation, as
illustrated in Figure 4A. Anti-IL-4 mAb treatment also led to
accelerated rejection and abolished the effect of rIL-5 treatment
on allograft survival (n=4) (Figure 4B). All rats totally rejected
their heart grafts by day 17 and there was no recovery in graft function
over the next 10 days. All MRCox81 treated rats rejected faster than sham treated controls (Figure 3B and
Figure 4B). MRCox81 and rIL-5 treated group had significantly lower graft function scores (Figure 4B) compared
to those from rats treated with rIL-5 alone, on all monitoring
days from day 11 (p<0.01) (Figure 4B).

Histology of Heart Grafts in rIL-5 Treated
Hosts: rIL-5 Treatment Reduced
Mononuclear Cell Infiltration and Damage
to Myocytes
The experimental protocol for obtaining Lewis heart graft tissue
from F344 rats for histology is illustrated in Figure 5A. Heart
grafts from rIL-5 treated rats taken at day 16 post-transplant had
good cardiac myocyte preservation with scattered mononuclear
cells infiltration (Figure 5B). In contrast, grafts from sham
treated rats had wide-spread myocyte necrosis and large
infiltrates of mononuclear cells. Additional examples are in
Supplementary Figure 1. Donor Lewis hearts in F344 recipients treated with rIL-5 and either anti-CD25 or anti-IL-4
mAb had massive areas of myocyte necrosis with dense infiltrates
of mononuclear cells, however these heart grafts were taken at
the end of the experiment at day 30 not at day 17 post-
transplant (Figure 5B).

Image analysis of donor hearts showed the pixels occupied
by necrotic myocytes was less in rIL-5 treated 139,475 ± 35,078
than in sham treated controls 474,969 ± 154,423 (p=0.00011);
anti-IL-4 mAb and rIL-5 treated 436,217 ± 138,148 and
anti-CD25 mAb plus rIL-5 treated 536,889 ± 272,577
(Figure 5C). The area of mononuclear cells measured by
pixels was less in rIL-5 treated 193,883 ± 108,701 than in sham
treated controls, 311,412 ± 124,968 (p=0.03), anti-IL-4
mAb and rIL-5 treated 269,521 ± 35,636 and anti-CD25 mAb
plus rIL-5 treated 249,281 ± 102,820 (Figure 5C). The mAb
treated animals grafts were collected two weeks longer post-
transplant and had established rejection, thus this data is not
directly comparable.

Characterization of the mononuclear cell infiltrate in heart
grafts using immunostaining with mAb, (Figure 5D), showed
that compared to grafts from sham treated hosts that were
rejected, rIL-5 treated grafts had significantly fewer CD8+ cells
(p=0.02), CD4+ cells (p<0.05) and Foxp3+ cells (p=0.05). 44%
of CD4+ cells in IL-5 treated expressed Foxp3, whereas 41.9%
expressed Foxp3 in rejected grafts. Representative sections are
shown in Supplementary Figure 2. There was no difference in
the infiltrate of ED1+ macrophages between sham treated and
rIL-5 treated.

Thus, rIL-5 treatment preserved the heart graft from injury
and markedly reduced the mononuclear cell infiltrate compared
to grafts from sham-treated rats. The benefits of rIL-5 treatment
were abolished by treatment with anti-CD25 mAb or anti-IL-4
mAb (Figures 5A–D).

Effect of Treatment With rIL-5 for 10 Days
on CD4+CD25+T Cells in Peripheral
Lymphoid Organs of Hosts
The source of lymphocytes for these studies is illustrated in
Figure 6A. We examined CD4+CD25+ cells from graft bearing
hosts to examine if IL-5 administration resulted in
in vivo activation of Ts2 cells and/or Th2-like Treg as assessed by
in vitro proliferation with rIL-5 (Figures 6B–D) and RT-PCR of
key markers (Figures 7A, B).

Spleen and lymph node cells from rats treated with rIL-5 for
10 days were examined either at the end of rIL-5 treatment on
day 16 (Figure 6B), or on day 66 (Figure 6C) post-
transplantation. Cells from sham treated F344 rats with Lewis
heart graft were assessed at 56 days post-transplantation
(Figure 6D). The proportion of CD4+CD25+ cells in rIL-5
-treated rats was 6.3-7.8% (Figures 6B, C) compared to 4% in
sham-treated controls (Figure 6D). Foxp3+ cells were 2.8% - 4%
in rIL-5 treated rats and 6.6% in sham-treated controls (data
not shown).

The enriched CD4+CD25+ cells in all three groups were 80-
88% CD4+CD25+ cells (Figures 6B–D left panel), 94-99% CD3+,
<2.4% CD8+, and 61-70% Foxp3+ cells (data not shown). This is
within the standard enrichment of murine Treg using CD25.
Thus, 30-40% of cells in the enriched CD4+CD25+T cells were
Foxp3+ and not necessarily T regulatory cells. They may include
activated effector CD4+T cells.

Enriched CD4+CD25+ cells were tested for proliferation in
MLC (Figures 6B–D, middle and right panel) and their mRNA
tested by RT-PCR (Figures 7A, B). Enriched CD4+CD25+ T cells
from rIL-5 treated hosts taken 16 days post-transplant
(Figure 6B, middle panel), in absence of rIL-5 in culture, had
a greater response to Lewis, than to self (F344) or third party.
Such proliferation to graft alloantigen suggested increased
numbers of cells activated by graft alloantigens. rIL-5 in
cultures partially enhanced responses to specific donor Lewis,
but this was not significant, as seen in the Stimulation Index
FIGURE 5  |  rIL-5 treatment reduces myocyte necrosis and mononuclear cell infiltrates in Lewis heart grafts transplanted to F344 hosts. (A) Experimental Flow Chart. Representative animals from sham treatment and 10 day rIL-5 treatment (Figure 3) groups were sacrificed for study of histology, myocyte damage, and mononuclear cell infiltrates in their cardiac allografts. Some animals from anti-CD25 and anti-IL-4 mAb therapy together with rIL-5 treatment groups (Figure 4) were sacrificed for histological studies. (B) Photomicrographs of H&E sections of Lewis cardiac allografts from F344 hosts. Samples were taken at days 17-19 post-transplant shortly after daily rIL-5 treatment had stopped. Images taken by a Leica DFC 450C camera with 400X magnification on a Leica DM 2000 LED microscope. Heart grafts from sham-treated hosts had large areas of mononuclear cell infiltration and scattered infiltrate between myocytes (Top panel). There were wide areas of myocyte necrosis. Heart grafts from animals treated with rIL-5 had minimal mononuclear infiltration between myocytes and minimal myocyte necrosis (second panel). Grafts from hosts treated with rIL-5 that also received NDS61 an anti-CD25 mAb to deplete Treg (third panel) and MRCOX81 mAb to block IL-4 (bottom panel) had large areas of myocyte necrosis and cell infiltration. (C) Areas of mononuclear cell infiltrate and myocyte necrosis was assessed as pixels per high power field (HPF) in multiple images taken at 400 X magnification on a Zeiss Axioscope A1 microscope (Zeiss, North Ryde, Australia) using Image Pro Plus 6.2 software (Media Cybernetics, Rockville, MA). Data expressed as mean ± SD, *p < 0.05, **p < 0.001. Area of mononuclear cell infiltration measured in pixels was significantly less in grafts from rIL-5 treated rats than those from sham treated rats, 193,883 ± 108,701 vs 311,411 ± 124,968 (p = 0.03) (Figure 4C). Area of myocytes necrosis measured in pixels was significantly lower (p<0.0001) in heart grafts from rIL-5 treated rats than in hearts from sham treated controls (Figure 4C). (D) Immunostaining for mononuclear cells in heart grafts from F344 rats showing comparison of cell infiltrate in grafts from rIL-5 treated animals to those from sham treated. Grafts from sham-treated animals had significantly reduced area of CD4+ cells (p<0.05), CD8+ cells (p<0.05), and Foxp3+ cells (p<0.05) compared to those from sham treated animals. The ratio of Foxp3+ cells in CD4+ cells was similar in rIL-5 treated and sham-treated rejection controls. There was no difference in infiltration of ED1+ macrophages. Photomicrographs of these stained sections are in Supplementary Figure 2.
FIGURE 6 | Flow cytometry profiles and proliferation of CD4+CD25+ T cells from spleen and lymph nodes from F344 recipients of Lewis cardiac allografts. (A) Experimental flow chart with animal treatment and collection time of peripheral lymphoid tissues for FACS and MLC. All cell donors were F344 grafted with a Lewis heterotopic heart transplant. Cells from rIL-5 treated were taken at 16 days post transplantation at the end of 10 days rIL-5 treatment, or at 66 days post-transplant. Sham treated recipients’ cells were taken at 56 days post-transplant. (B–D) Enriched CD4+CD25+ T cells (left column) from lymph nodes and spleens from Lewis allograft bearing F344 recipients were examined for their capacity to proliferate in MLC in response to no stimulator cells (Nil), or stimulator cells from self (F344), specific donor (Lewis) or third party PVG. The understanding of the current findings is dependent upon our previous findings. First, naïve CD4+CD25+ T cells, in the absence of rIL-2 or IL-4 have a very small response to alloantigen, and none to self. CD4+CD25+ T cells from tolerant hosts do not respond to the tolerated donor strain but they do respond to third party. The proliferation of CD4+CD25+ T cells from tolerant hosts to specific donor, but not to self or third party is enhanced by addition of cytokines such as rIL-5. Effect of rIL-5 on proliferation of CD4+CD25+ T cells to self and specific donor is shown in middle column. Proliferation to third party PVG, which is fully allogeneic, is much larger to self and Lewis (data not shown). Stimulation indices were calculated as proliferation with rIL-5 in culture divided by the proliferation to the same donor stimulator cells with no rIL-5 (n=6). (B) Cells from hosts treated with rIL-5 taken at day 16 post-transplant. CD4+CD25+ T cells represented 7.8% of unfractionated lymphocytes and 87% of enriched cells (left panel). The enriched CD4+CD25+ T cells proliferated to specific donor, but not to self (middle panel). This proliferation was slightly enhanced by adding rIL-5 to cultures, but not significantly when assessed as Stimulation Index (right panel). (C) Cells from hosts given sham treatment taken at 56 days post-transplantation had similar proportions of CD4+CD25+ cells (6.6%) to animals treated with rIL-5. However, these cells did not respond to specific donor alone, and rIL-5 did not enhance proliferation (middle and right panel), indicating absence of alloantigen-specific Treg that depend upon IL-5. *p < 0.5, **p < 0.01, ***p < 0.05.
FIGURE 7 | RT-PCR assays of mRNA for transcription factors, cytokines and cytokine receptors in CD4+CD25+ T cells from F344 rats. (A) Comparison of RT-PCR of mRNA of CD4+CD25+ T cells from naïve F344 to those from F344 rats bearing Lewis heart graft treated with rIL-5 for 10 days. CD4+CD25+ cells were enriched from lymph node and spleens of F344 rats as described in methods and subjected to mRNA extraction. mRNA prepared at 16 days post transplantation from F344 rats bearing Lewis heart grafts and treated with rIL-5 for 10 days was compared to that from naive F344 rats that had no transplant and no treatment (Experimental Flow Chart). mRNA was subjected to cDNA extraction followed by RT-PCR of transcription factors, cytokines and cytokine receptors associated with activation of naïve CD4+CD25+ T cells by alloantigen and either IL-2 (Ifngr, I12rb2) or IL-4 (Irf4 and Il5ra). CD4+CD25+ T cells from rIL-5 treated graft bearing hosts had more Foxp3 consistent with activation of Treg, and more Il5, and Irf4, consistent with induction of Th2-like Treg. There was also induction of Ifngr, Ilng and I12rb2 consistent with induction of Treg by Type-1 cytokines (28, 29). *p < 0.05, **p < 0.01, ***p < 0.001. (B) Comparison of RT-PCR of mRNA from CD4+CD25+ cells from F344 hosts with Lewis heart graft at >56 days. CD4+CD25+T cells from spleen and lymph nodes of F344 rats treated with rIL-5 for short term (10 days) or long-term were compared to those from sham treated hosts (Experimental Flow Chart). CD4+CD25+T cells in long-term rIL-5 treated animals were not increased and was ~6.4% (data not shown), similar to those from short-term rIL-5 treated and sham- treated rats (Figure 6). CD4+CD25+T cells from long-term treatment group had greater expression of Foxp3, Irf4 and Il5 than cells from recipients where rIL-5 treatment was given only for 10 days that stopped at 16 days post transplantation. Cells from sham treated rats had less expression of Th2-like Treg markers than those from rats given short term rIL-5 treatment. Thus, continued rIL-5 treatment strongly retained the Th2-like Treg phenotype. *p < 0.05, **p < 0.01, ***p < 0.001.
Enriched CD4⁺CD25⁺ cells (>88%) from F344 rats with Lewis heart grafts, treated for 10 days with rIL-5, at day 66 post-transplantation had no proliferation to specific-donor in the absence of rIL-5 (Figure 6C, middle panel). This was consistent with our previous observations that Treg from rats with transplant tolerance do not proliferate to specific-donor in the absence of key cytokines (26, 31). rIL-5 in culture enhanced their proliferation to specific-donor Lewis with a Stimulation Index that was significantly greater than that to self (p<0.01) and third-party PVG (p<0.001) (Figure 6C right panel). Proliferation to self or to third-party was not enhanced by addition of rIL-5. (Figure 6C, right panel).

CD4⁺CD25⁺ cells from sham-treated hosts, alone or with rIL-5 had no proliferation to specific donor, self or third-party simulators (Figure 6D, middle panel). These animals had rejected their grafts and would not be expected to have activated Treg surviving 56 days post-transplant. Cultures of CD4⁺CD25⁺ cells from rats receiving long-term rIL-5, taken at day 60 post-transplantation, failed due to malfunction of an incubator and could not be repeated due to animal ethics issues.

RT-PCR of mRNA for Transcription Factors, Cytokines and Cytokine Receptors on CD4⁺CD25⁺ Cells From F344 Rats With Lewis Heart Grafts

RT-PCR of mRNA from CD4⁺CD25⁺ T cells from peripheral lymphoid tissue of heart grafted animals taken on day 16 at the end of treatment for 10 days with rIL-5 was performed. Controls were CD4⁺CD25⁺ cells from naive F344 animals that had not been transplanted with a heart graft and had no treatment (Figure 7A). CD4⁺CD25⁺ T cells from heart graft recipients treated with rIL-5 had significantly greater expression of foxp3 (p<0.001), Irf4 (p<0.05), Il5 (p<0.001), and higher Il5Ra (not significant) compared to CD4⁺CD25⁺ T cells from naive F344 rats. These findings suggested that rIL-5 treatment activated Th2-like Treg, which expressed Irf4 and Il5. There was also induction of Th1-like Treg markers Ilfng and Il2rb2 (p<0.001) and Ifng (p<0.01), showing Th1-like Treg were also present.

CD4⁺CD25⁺ cells from rIL-5 and sham treated rats were also compared at around 60 days post transplantation (Figure 7B). CD4⁺CD25⁺ cells from long-term rIL-5 treated rats on day 60 post-transplantation, expressed more mRNA for Foxp3 (p<0.01), Irf4 (p<0.05) and Il5 (p<0.01) than those from sham-treated rats with heart grafts, at 56 days post-transplantation. Sham treated rats did not receive rIL-5 and had rejected by day 31 post-transplant. The cells from short-term rIL-5 treated group (66 days post-transplantation), also had an increase in Foxp3 (p<0.001), Irf4 (p<0.01) and Il5 (p<0.001) compared to sham-treated at day 56 post-transplantation. Expression of Th1-like Treg marker Ifng (p<0.01) was also increased, but Ifngr and Il12rb2 were not (Figure 7B).

DISCUSSION

Treatments to promote transplant tolerance could improve long-term allograft survival in patients. Immunoregulation is a complex process that involves a number of Treg pathways (23, 27, 43). In rodent models transplant tolerance is mediated by CD4⁺CD25⁺ T cells (16, 17) that express Foxp3. During immune response to newly transplanted tissues, a variety of T effector cells are activated and can mediate rejection, including Th1 (44), Th2 (44, 45) and Th17 cells (46, 52, 55). Cytokines produced by these activated Th cells promote distinct pathways of activation of CD8⁺ T cells, macrophages, and B cells. This study adds to a growing body of work showing they also activate distinct Treg pathways (23, 28, 29, 43) to produce different subclasses of Treg, which contribute to tolerance to an allograft (43).

Resting/naive Treg are activated during all rejection responses, and can, if the graft is not totally destroyed, dominate rejection and allow recovery of graft function. In the model used, Lewis grafts in F344 recipients, one in ten grafts undergo transient rejection but fully recover and have good function long-term. This process is usually dominated by Type-1 activated Treg. In this study, rIL-5 treatment delayed rejection and allowed this natural regulatory process to dominate, permitting all grafts in rIL-5 treated host to survive without any immunosuppression. Thus, Type-2 activated Treg augmented the Type-1 activated Treg to inhibit the rejection response and promote tolerance to the allograft. In the short term rIL-5 treated the cessation of rIL-5 resulted in more rejection, however over time the grafts recovered and gained function similar to long term rIL-5 treated. We attributed this rejection to loss of IL-5 to promote Ts2 cells. The later recovery occurs if rejection is not total and is seen in a small proportion of F344 rats with Lewis heart grafts. We attribute this to induction of activated Treg by the grumbling rejection response.

Apart from delaying complete allograft rejection, less myocyte necrosis and mononuclear cells infiltration was identified in grafts in rIL-5 treated hosts. There was significantly fewer CD4⁺, CD8⁺, Foxp3⁺ infiltrating T cells in grafts of rIL-5 treated rats but macrophage infiltration was not reduced.

The best-defined pathway of activation of naïve/resting CD4⁺CD25⁺Foxp3⁺ Treg involves Type-1 cytokines. This activation is a two-step process. In the first step, IL-2 activates naïve/resting Treg, and in the presence of alloantigen generates donor-specific activated Treg (28, 29, 50, 51) that express receptors for Type-1 cytokines, including IL-12 and IFN-γ (28, 29, 51). We identified these Ts1 cells by using Type I cytokines to activate CD4⁺CD25⁺ cells from a naïve host in vitro (28, 29, 51). In the second step of activation the phenotype of Ts1 cells can be further modified by stimulation to specific donor alloantigen and IL-12 (28) in the absence of IL-2. This second step induces Th1-like Treg to express both Foxp3 and Tbet, also to produce Ifng but not Il2. These Th1-like Treg are much more potent at suppressing rejection than Treg or Ts1 cells (28). Th1-like Treg markedly delay rejection of fully allogeneic heart grafts (28).

CD4⁺CD25⁺ cells from animals with transplant tolerance, which includes alloantigen specific Treg, do not proliferate to
specific donor alloantigen in vitro, but they can proliferate to donor alloantigen if either IFN-γ or IL-12 are present in the culture medium (28, 29). Treatment with rIL-12 in some models can delay rejection of an allograft, and this effect requires IFN-γ (54). IFN-γ has been shown by others to promote expansion of antigen-specific Treg (56, 57). Thus, IL-12 and/or IFN-γ may promote induction of Th1-like Treg and promote tolerance. Both of these Type-1 cytokines have the potential to also promote Th1 responses and rejection, however.

Relevant to this study is the pathway of activation of naïve/resting CD4+CD25+ cells by antigen and Type-2 cytokines (Figure 1) (29, 30, 32, 43). In the first step, tTreg activated by alloantigen and IL-4, in the absence of rIL-2 in the culture, are induced to express mRNA for the receptor of the Type-2 cytokine IL-5, not the receptors for Type-1 cytokines IFN-γ and IL-12 (29). These activated tTreg we named Ts2 cells (29). In a second step, Ts2 cells further proliferate in the presence of IL-5 and specific alloantigen to become Th2-like Treg. Therapy with rIL-5 inhibits acute allograft rejection and induction of Th1 and Th17 responses (34) and promotes Ts2 cells (30, 32). IL-5 promotes survival of transplant tolerance transferring CD4+T cells, which die ex vivo without key cytokines, one of which is IL-5 (33). CD4+CD25+ cells from animals with transplant tolerance do not respond to specific donor alloantigen unless key cytokines such as IL-5 are present (31). In this study, CD4+CD25+ cells from rIL-5 treated, but not sham treated, hosts had a proliferative response to specific donor that was enhanced by rIL-5 in culture.

In this study, the Type-2 cytokine milieu did not inhibit induction of Ts1 and Th1-like Treg especially early on at day 16. Longer term, at around 60 days post-transplant where rIL-5 therapy was stopped at day 16 post-transplant, molecules associated with Th1-like Treg were also induced in CD4+CD25+Foxp3+Treg. Thus, Type 1 and Type 2 activated Treg can be activated in parallel and are not mutually exclusive.

For some time, Th2 responses were thought to promote transplant tolerance (44, 58).

Although therapy with rIL-4 (59, 60) or rIL-13 (61) delayed rejection, in other models rIL-4 promoted rejection (62–64). Further, in adaptive transfer studies allospecific Th2 cells mediate rejection (44, 45). Th2 cytokines are produced during normal rejection where there is induction of Th2 cells that contribute to normal allograft rejection responses (38, 65).

We concluded that the effects of rIL-5 in this study are attributed to its role in activation of Type-2 Treg. IL-5 is a cytokine produced by Th2 cells and some regulatory T cells including Tr1 and Ts1 cells (29, 66). IL-5 is produced long-term by Th2 cells, after the initial burst of IL-4 production diminishes. IL-5 acts by binding to a specific IL-5 receptor, IL-5Rα, which has limited expression. In man, IL-5Rα is mainly expressed on eosinophils, basophils and mast cells, and their progenitors (67). IL-5Rα is not expressed by human effector T cells including Th1, Th2, Th17 cells, nor APC, monocytes and macrophages (67). Over 30 years ago, IL-5 was reported to act with IL-2 to induce cytotoxic T cells (68), but this finding has not been reproduced. Until we described IL-5Rα expression on IL-4 and antigen activated Treg and the capacity of IL-5 to promote their proliferation and expansion (21, 23), there was no solid evidence that IL-5 activated any T cells. We showed that human Treg activated by alloantigen and rIL-4 (not rIL-2) also are induced to express IL-5Rα (30).

rIL-5 can activate CD5+B1 cells that express IL-5Rα (69) to produce natural IgM antibodies in response to bacterial stimulation (70, 71). IL-5 promotes murine, but not human, B cells to switch to produce non-complement fixing immunoglobulin isotypes IgG1 and IgE (67). IL-5 therapy in autoimmune does not induce a switch in Ig isotypes nor reduce Ig titres (30). IL-5, but not IL-4, induces expression of CD25 on activated B cells (72, 73) and leads to release of soluble CD25 (74), which could consume IL-2. The effect of IL-5 on B cells, as well as of anti-CD25 mAb on activated B cells, was not examined. We cannot exclude that B cells activation contributed to the rIL-5 effect on allograft rejection.

The results of this study are consistent with our findings in autoimmune models that rIL-5 therapy reduces immune inflammation (30, 32). The allograft model we used has only a class I MHC and multiple minor incompatibilities (38, 39, 75) making rejection slower than with both a class I and II MHC mismatch. In a neonatal heart transplant model, rIL-5 therapy delayed rejection and inhibited production of IFN-γ and IL-2.

Our findings of accelerated rejection by blocking IL-4 or by depleting CD25+ cells are consistent with CD4+CD25+ Treg in the host being activated to Ts2 cells by alloantigen and the IL-4 produced by the alloantigen-activated effector T cells. In autoimmunity, blocking IL-4 and depleting CD25+ cells also abrogate the ability of rIL-5 to promote Ts2 cells to reduce immune injury (30, 32). In both autoimmune and allograft rejection, the activation of Treg by Type-2 cytokines reduces inflammation.

In this study, we showed that Ts2 cells re-cultured with the same donor alloantigen and rIL-5 were induced to express mRNA for the Th2 transcription factors Gata3 and Irf4, together with il5. Thus, in vitro we showed induction of Th2-like Treg. The CD4+CD25+ T cells from rats with an allograft that had been treated with rIL-5 long-term had cells with a Th2-like Treg phenotype, in that they expressed Foxp3, Irf4 and Il5. Irf4 is a transcription factor that is induced by TCR activation by antigen (76, 77) and the activation of a variety of immune cells in a Type 2 response (78) including antigen-activated Treg that control Th2 responses (36, 37). GATA-3 is the master transcription factor for Th2 responses. Further, in this study we showed in vitro induced Th2-like Treg expressed mRNA for Il5, which is not expressed by naïve Treg or Ts2 cells. The findings in this study were consistent with rIL-5 therapy promoting antigen-specific Treg that include Th2-like Treg.

In our studies in several models of alloimmunity (34) and autoimmune (30, 32, 79), rIL-5 therapy was well tolerated. Mice with transgenes for IL-5 have high levels of IL-5 and eosinophilia, but remain healthy (38, 39, 80). High levels of IL-5 produced by Th2 responses to parasitic infections induces eosinophilia but has no adverse effects. The impairment of autoimmunity by parasitic infection in part depends on IL-5 and CD25+ T cells activated by IL-4 (23).
CD4⁺CD25⁺ cells from heart grafted animals treated with rIL-5 for 10 days, at the end of rIL-5 treatment, had increased proliferation to specific donor Lewis that was partially enhanced by addition of rIL-5 to cultures. These cells did not respond to self or third-party stimulator cells, even in the presence of rIL-5.

CD4⁺CD25⁺ cells of animals treated for 10 days with rIL-5, whose allografts survived >60 days, lacked reactivity to specific donor alloantigen unless rIL-5 was present in the cultures. These findings are consistent with an alloantigen-specific response of the tolerant CD4⁺CD25⁺ T cells, we have recently described (31). Briefly, CD4⁺CD25⁺ T cells from animals tolerant to a graft have no reactivity to donor antigen in the absence of cytokines such as IL-5 (31). Tolerant Type-2 cytokine activated Treg are dependent on IL-5, so cells have no response if rIL-5 is not present. Moreover, in the absence of rIL-5 in vitro, the alloantigen-specific Ts2 cells did not survive and other Treg, such as Ts1 and Th1-like Treg were activated. These results suggest that rIL-5 therapy may need to be given long-term to sustain the Ts2 cells and induce Th2-like Treg that express IRF4 and produce IL-5.

The mechanisms by which antigen specific Treg suppress rejection are not fully understood. They can enter the sites of inflammation in the graft, where they neutralize effector responses, including by production of adenosine by CD39 and CD73 expressed by activated Treg (81). Other less well understood mechanisms require direct Treg contact with effector cells that appear to involve Class II MHC on activated Treg and release of perforin and granzyme. Studies of the effector function of activated Treg are complicated by their dependence on specific antigen stimulation and cytokines such as IFN-γ (29, 31, 82) and IL-12 (28, 31) in the case of Type-1 activated Treg, or IL-5 in the case of Type 2 activated Treg (31, 33). Antigen-specific Treg die in culture without the cytokines required to support their survival (31, 83), and do not suppress proliferation of effector T cells in vitro (31, 84, 85). This is a distinct difference to naïve/resting tTreg which inhibit antigen presenting cells and reduce activation of naïve effector T cells (25). Given there is no assay for assessing suppression of activated alloantigen specific CD4⁺CD25⁺Foxp3⁺ Treg in vitro, we were unable to assess their function ex vivo.

This study showed rIL-5 promoted induction of Treg that inhibited rejection to promote induction of tolerance. The inability of IL-5 to promote effector T cells makes it a better candidate for induction of tolerance than Type-1 cytokines IFN-γ (56, 57, 82, 86, 87) or IL-12 (28, 29) that promote Th1-like Treg but also promote Th1 responses and NK cells. Type-I induced and activated Treg were also generated in rIL-5 treated hosts demonstrating the pathways were complimentary and not mutually exclusive.

Although a variety of regulatory mechanisms have been described to promote transplant tolerance, the dominant regulatory mechanism in most models involves CD4⁺CD25⁺ Foxp3⁺ Treg (16, 17, 23, 31, 43). Human CD4⁺CD25⁺ CD127⁻ Treg activated by rIL-4 and alloantigen express IL-5Rx (27). Thus, therapy with rIL-5 or an analogue may be of use to induce antigen-specific activated CD4⁺CD25⁺ Treg in man and suggests a new pathway to control ongoing rejection.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

The animal study was reviewed and approved by University of New South Wales Animal Ethic Committee.

AUTHOR CONTRIBUTIONS

BH: Participated in research design, writing of paper, and data analysis. RH: Participated in conduct of research, writing of paper, and data analysis. GT: Participated in conduct of research, writing of paper, and data analysis. CR: Participated in conduct of research, writing of paper, and data analysis. PW: Participated in conduct of research, writing of paper, and data analysis. PR: Participated in conduct of research. AS: Participated in research design, writing of paper, and data analysis. NV: Participated in research design, conduct of research; writing of paper, and data analysis. SH: Participated in research design, writing of paper, and data analysis. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by funding from South West Sydney Local Health District, The University of New South Wales, Sydney and anonymous donations.

ACKNOWLEDGMENTS

We appreciate the expert animal breeding and care of Mr Moheb Botros. We thank Ranje Al-atiyah for assistance with the illustrations and Dr Murray Killingworth for image analysis.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.714838/full#supplementary-material

Supplementary Figure 1 | Photomicrographs (x40) of transplanted Lewis heart grafts in F344 recipients.

Supplementary Figure 2 | Photomicrographs (x40) of transplanted Lewis heart grafts in F344 recipients. Comparison of grafts from sham and rIL-5 treated recipients. Immunoperoxidase staining with monoclonal antibodies to CD4, CD8, Foxp3 and ED1 (a macrophage marker). Quantitation of infiltrate shown in Figure 4D.
44. Barbara JA, Hancock WW, Akalin EA, Glyning-Jensen T, Willett TA, et al. Chronic Cardiac Rejection in the LEW to F344 Rat Model. Blockade of CD40L+ infused T cells: Constituency for CTLA-4 and CTLA-4 Modulation in Murine Cardiac Allograft Rejection. J Immunol (1996) 156(4):1392–1396.

45. Adams DH, Russell ME, Hancock WW, Sayegh MH, Wyner LR, Karnovsky TA, et al. Chronic Cardiac Rejection in the LEW to F344 Rat Model. Blockade of CD40L+ infused T cells: Constituency for CTLA-4 and CTLA-4 Modulation in Murine Cardiac Allograft Rejection. J Immunol (1996) 156(4):1392–1396.

46. Itoh S, Nakae S, Axtell RC, Velotta JB, Kimura N, Kajiware N, et al. IL-17 Cytokines in Alloimmunity. J Immunol (2005) 174(9):5640–5646.

47. Ferguson GC, Wood KJ, Bushell A. Interferon-Gamma Conditioning Ex Vivo Generates CD56–CD16+FOX3+ Regulatory T Cells That Prevent Allograft Rejection: Potential Avenues for Cellular Therapy. Transplantation (2008) 86:578–89. doi: 10.1097/TP.0b013e3181086a60

48. Tran GT, Hodgkinson SJ, Carter NM, Killinsworth M, Nomura M, Verma ND, Robinson CM, Tran GT, Hodgkinson SJ, Hall BM. Induction of Interleukin-13 Prolongs Allograft Survival: Association With Inhibition of Macrophage Cytokine Activation. Transpl Immunol (2007) 173(1):78–86. doi: 10.1016/j.trim.2006.09.035

49. Verma ND, Robinson CM, Carter N, Wilcox P, Tran GT, Hodgkinson SJ, Hall BM. Posttransplant Interleukin-4 Treatment Converts Rat Liver Allograft Tolerance to Rejection. Transplantation (2005) 79(9):1116–20. doi: 10.1097/01.TP.0000161249.20922.16

50. Piccirillo JR, Chan SY, Vanbuskirk AM, Eichwald EJ, Bishop DK. Are Th2 Helper T Lymphocytes Beneficial, Deleterious, or Irrelevant in Promoting Allograft Survival. Transplantation (1997) 63(5):619–24. doi: 10.1097/00007890-199703150-00001

51. Mitchell P, Aifazzi B, Lombardi G, Lechler R. The Th Helper 17– Regulatory T Cell Axis in Transplant Rejection and Tolerance. Curr Opin Organ Transplant (2009) 14(4):326–31. doi: 10.1097/MOT.0b013e32832ae388e

52. Sanderson CJ, Interleukin-5, Eosinophils and Disease. Blood (1992) 79(12):3101–9. doi: 10.1182/blood.V79.12.3101.bloodjournal79123101

53. Perry MJ, Boyd RA, Hall BM. Role of T Cells in the Mediation of Heymann Nephritis. II. Identification of Th1 and Cytotoxic Cells in Glomeruli. Kidney Int (1997) 51:1059–68. doi: 10.1038/ki.1997.148

54. Verma ND, Boyd R, Robinson CM, Plain KM, Tran GT, Hall BM. Interleukin-12p70 Prolongs Allograft Survival by Induction of Interferon Gamma and Nitric Oxide Production. Transplantation (2006) 82(10):1324–33. doi: 10.1097/01.TP.0000239519.56358.c1

55. Antonsamy MA, Fandow WC, Fu F, Li W, Qian S, Troudt AB, et al. Evidence for a Role of IL-17 in Alloimmunity: A Novel IL-17 Antagonist Promotes Heart Graft Survival. Transplant Proc (1999) 31(1-2):83. doi: 10.1016/S0041-1345(98)01453-5

56. Cheng W, Gao W, Storb TB, Ouakmam M, Francis SM, Wood KJ, et al. Exogenous IFN-γ/Interleukin-12 Promotes Cytotoxic T-Cell Repertoire by Inhibition of Th17 Responses and Generation of Functional Foxp3+ Regulatory T Cells. Eur J Immunol (2008) 38(9):2512–27. doi: 10.1002/eji.2008038411

57. Poudrier J, Owens T. The Acquisition of Cytokine Responsiveness by Murine B Cells: A Role for Antigen and IL-5 in the Induction of IL-2 Receptors. Immunology (1994) 81(3):373–80.

58. Loughnan MS, Sanderson CJ, Nossal GI. Soluble Interleukin 2 Receptors Are Released From the Cell Surface of Normal Murine B Lymphocytes Stimulated...
With Interleukin 5. Proc Natl Acad Sci USA (1988) 85((9):3115–9. doi: 10.1073/pnas.85.9.3115
75. Adams DH, Wyner LR, Karnovsky MJ. Experimental Graft Arteriosclerosis. II. Immunocytochemical Analysis of Lesion Development. Transplantation (1993) 56(4):794–9. doi: 10.1097/00007890-199310000-00004
76. Mittrücker H-W, Matsuyama T, Grossman A, Kündig TM, Potter J, Shahinian A, et al. Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function. Science (1997) 275(5299den):540–3. doi: 10.1126/science.275.5299.540
77. Li P, Spolski R, Liao W, Leonard WJ. Complex Interactions of Transcription Factors in Mediating Cytokine Biology in T Cells. Immunol Rev (2014) 261(1):141–56. doi: 10.1111/imr.12199
78. Gao Y, Nish SA, Jiang R, Hou L, Licona-Limón P, Weinstein JS, et al. Control of T Helper 2 Responses by Transcription Factor IRF4-Dependent Dendritic Cells. Immunity (2013) 39(4):722–32. doi: 10.1016/j.immuni.2013.1008.1028
79. Traugott U, Reinherz EL, Raine CS. Multiple Sclerosis: Distribution of T Cell Subsets Within Active Chronic Lesions. Science (1983) 219(4582):308–10. doi: 10.1126/science.6217550
80. Dent LA. Eosinophilai in Transgenic Mice Expressing IL-5. J Exp Med (1990) 172(5):1425–31. doi: 10.1084/jem.172.5.1425
81. Dwyer KM, Deaglio S, Gao W, Friedman D, Strom TB, Robson SC, CD39 and Control of Cellular Immune Responses. Partnerenic Signal (2007) 3(1-2):171–80. doi: 10.1007/s11302-006-9050-y
82. Nomura M, Hodgkinson SJ, Tran GT, Verma ND, Robinson C, Plain KM, et al. Cytokines Affecting CD4+T Regulatory Cells in Transplant Tolerance. Interferon-Gamma (IFN-G) Promotes Survival of Alloantigen Specific CD4+ T Regulatory Cells. Transplant Immunol (2017) 42(Jun):24–33. doi: 10.1016/j.trim.2017.1005.1002
83. Pearce NW, Spinelli A, Gurlay KE, Hall BM. Specific Unresponsiveness in Rats With Prolonged Cardiac Allograft Survival After Treatment With Cyclosporine. VI. In Vitro Alloreactivity of T Cell Subsets From Rats With Long-Surviving Allografts. Transplantation (1993) 55(2):374–80. doi: 10.1097/00007890-199302000-00027
84. Nicolls MR, Aversa GG, Pearce NW, Spinelli A, Berger MF, Gurlay KE, et al. Induction of Long-Term Specific Tolerance to Allografts in Rats by Therapy With an Anti-CD3-Like Monoclonal Antibody. Transplantation (1993) 55(3):459–68. doi: 10.1097/00007890-199303000-00001
85. Willenborg DO, Fordham SA, Staykova IM, Ramshaw IA, Cowden WB. Interferon-Gamma Is Critical to the Control of Murine Autoimmune Encephalomyelitis and Regulates Both in the Periphery and in the Target Tissue; a Possible Role for Nitric Oxide. J Immunol (1999) 163:5278–86.
86. Feng G, Wood KJ, Bushell A. Regulatory T Cell Enrichment by IFN-G Conditioning. Methods Mol Biol (2011) 677:281–301. doi: 10.1007/978-1-60761-869-0_20

Conflict of Interest: BH and SH hold patents related to production of antigen specific Treg and tests of tolerance related to this work. The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Hall, Hall, Tran, Robinson, Wilcox, Rakesh, Wang, Sharland, Verma and Hodgkinson. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.